Načítá se...
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and transthyretin (ATTR) amyloidosis have been limited. However, there are...
Uloženo v:
| Vydáno v: | JACC Basic Transl Sci |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6609907/ https://ncbi.nlm.nih.gov/pubmed/31312767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2019.02.002 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|